Exelixis to present Cabometyx, zanzalintinib studies at ASCO annual meeting
PUBT · 1d ago
Share
Listen to the news
- Exelixis will present data on cabozantinib and investigational zanzalintinib at the 2026 American Society of Clinical Oncology Annual Meeting, May 29 to June 2, in Chicago.
- Key readouts include new analyses from the phase 3 CABINET trial for cabozantinib, with additional results from the phase 3 STELLAR-303 trial evaluating zanzalintinib in metastatic colorectal cancer.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Exelixis Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260521232880) on May 21, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending